US2014141013A1PendingUtilityA1
Anti-il-6 antibodies, compositions, methods and uses
Est. expiryNov 14, 2021(expired)· nominal 20-yr term from priority
A61P 5/14A61P 9/14A61P 35/04A61P 7/08A61P 3/06A61P 37/00A61P 7/04A61P 37/02A61P 5/00A61P 37/06A61P 9/04A61P 9/10A61P 37/08A61P 37/04A61P 43/00A61P 7/02A61P 3/10A61P 7/06A61P 7/00A61P 31/00A61P 35/00A61P 31/04A61P 27/02A61P 31/16A61P 3/04A61P 25/30A61P 31/08A61P 35/02A61P 29/00A61P 31/10A61P 31/18A61P 31/12A61P 33/06A61P 25/00A61P 25/32A61P 11/16A61P 15/00A61P 11/02A61P 1/04A61P 1/10A61P 1/16A61P 13/12A61P 11/14A61P 13/02A61P 17/06A61P 17/02A61P 17/12A61P 17/14A61P 1/00A61P 19/02A61P 17/04A61P 1/08A61P 21/04A61P 1/18A61P 11/06A61P 19/10A61P 11/00A61P 17/00A61P 11/04C07K 2317/24C07K 16/4241A61K 2039/505C07K 16/248C07K 2317/565A01K 2267/0331C07K 2317/76C07K 2317/92C07K 2317/73A01K 67/0271A61K 39/3955
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Claims
exact text as granted — not AI-modified1 .- 41 . (canceled)
42 . A method for treating a lymphoproliferative disorder or disease in a cell, tissue, organ or animal, comprising; contacting or administering an effective amount of at least one IL-6 antibody or specified portion or variant comprising the heavy chain and light chain complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS:1-6, and a constant region derived from one or more human antibodies with, or to, said cell, tissue, organ or animal.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.